Browse > Article
http://dx.doi.org/10.3904/kjim.2014.29.3.325

Follicular and Hurthle cell carcinoma of the thyroid in iodine-sufficient area: retrospective analysis of Korean multicenter data  

Kim, Won Gu (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Kim, Tae Yong (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Kim, Tae Hyuk (Department of Internal Medicine, Seoul National University College of Medicine)
Jang, Hye Won (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Jo, Young Suk (Department of Internal Medicine, Chungnam National University School of Medicine)
Park, Young Joo (Department of Internal Medicine, Seoul National University College of Medicine)
Kim, Sun Wook (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Kim, Won Bae (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Shong, Minho (Department of Internal Medicine, Chungnam National University School of Medicine)
Park, Do Joon (Department of Internal Medicine, Seoul National University College of Medicine)
Chung, Jae Hoon (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Shong, Young Kee (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Cho, Bo Youn (Department of Internal Medicine, Chung-Ang University College of Medicine)
Publication Information
The Korean journal of internal medicine / v.29, no.3, 2014 , pp. 325-333 More about this Journal
Abstract
Background/Aims: Follicular thyroid carcinoma (FTC) and Hurthle cell carcinoma (HCC) of the thyroid are relatively uncommon thyroid malignancies in iodine- sufficient areas. In this study we evaluated the clinical behavior, prognostic factors and treatment outcomes of FTC and HCC in Korea. Methods: This multicenter study included 483 patients with FTC and 80 patients with HCC who underwent an initial surgery between 1995 and 2006 in one of the four tertiary referral hospitals in Korea. We evaluated clinicopathological factors associated with distant metastases and recurrence during a median of 6 years of follow-up. Results: HCC patients were significantly older (49 years vs. 43 years; p < 0.001) and had more lymphovascular invasions (22% vs. 14%; p = 0.03) compared with FTC patients. Distant metastases were confirmed in 40 patients (8%) in the FTC group and in two patients (3%) in the HCC group (p = 0.07). Distant metastases were significantly associated with older age, widely invasive cancer and extrathyroidal invasion. Only 14 patients (3%) had recurrent disease and there was no significant difference between FTC and HCC groups (p = 0.38). Recurrence was associated with larger tumor size and cervical lymph node metastasis. Conclusions: HCC patients were older and had more lymphovascular invasions than FTC patients. However, FTC and HCC patients had similar initial clinicopathological features. Older age, wide invasiveness and extrathyroidal invasion were independent risk factors for predicting distant metastases in FTC and HCC patients.
Keywords
Follicular adenocarcinoma; Hurthle cell thyroid cancer; Distant metastases; Prognosis; Iodine;
Citations & Related Records
연도 인용수 순위
  • Reference
1 O'Neill CJ, Vaughan L, Learoyd DL, Sidhu SB, Delbridge LW, Sywak MS. Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion. Eur J Surg Oncol 2011;37:181-185.   DOI
2 American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214.   DOI   ScienceOn
3 Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008;36:425-437.   DOI   ScienceOn
4 Sorrenti S, Trimboli P, Catania A, Ulisse S, De Antoni E, D'Armiento M. Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hurthle cell neoplasm. Thyroid 2009;19:355-360.   DOI   ScienceOn
5 Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Diagn Cytopathol 2006;34:330-334.   DOI   ScienceOn
6 Lopez-Penabad L, Chiu AC, Hoff AO, et al. Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer 2003;97:1186-1194.   DOI   ScienceOn
7 Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988;67:501-508.   DOI
8 Goffredo P, Roman SA, Sosa JA. Hurthle cell carcinoma: a population-level analysis of 3311 patients. Cancer 2013;119:504-511.   DOI
9 Passler C, Scheuba C, Prager G, et al. Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region. Endocr Relat Cancer 2004;11:131-139.   DOI
10 D'Avanzo A, Treseler P, Ituarte PH, et al. Follicular thyroid carcinoma: histology and prognosis. Cancer 2004;100:1123-1129.   DOI   ScienceOn
11 Sugino K, Ito K, Nagahama M, et al. Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma. Thyroid 2011;21:751-757.   DOI
12 Baloch ZW, LiVolsi VA. Our approach to follicular-patterned lesions of the thyroid. J Clin Pathol 2007;60:244-250.
13 DeGroot LJ, Kaplan EL, Shukla MS, Salti G, Straus FH. Morbidity and mortality in follicular thyroid cancer. J Clin Endocrinol Metab 1995;80:2946-2953.
14 Brennan MD, Bergstralh EJ, van Heerden JA, McConahey WM. Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1991;66:11-22.   DOI   ScienceOn
15 Donohue JH, Goldfien SD, Miller TR, Abele JS, Clark OH. Do the prognoses of papillary and follicular thyroid carcinomas differ? Am J Surg 1984;148:168-173.   DOI   ScienceOn
16 Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 1989;63:908-911.   DOI   ScienceOn
17 Lo CY, Chan WF, Lam KY, Wan KY. Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival. Ann Surg 2005;242:708-715.   DOI   ScienceOn
18 Phitayakorn R, McHenry CR. Follicular and Hurthle cell carcinoma of the thyroid gland. Surg Oncol Clin N Am 2006;15:603-623.   DOI   ScienceOn
19 Ganly I, Ricarte Filho J, Eng S, et al. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab 2013;98:E962-E972.   DOI
20 Gosain AK, Clark OH. Hurthle cell neoplasms: malignant potential. Arch Surg 1984;119:515-519.   DOI
21 Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013;13:184-199.   DOI   ScienceOn
22 Correa P, Chen VW. Endocrine gland cancer. Cancer 1995;75(1 Suppl):338-352.   DOI   ScienceOn
23 Grebe SK, Hay ID. Follicular thyroid cancer. Endocrinol Metab Clin North Am 1995;24:761-801.
24 Asari R, Koperek O, Scheuba C, et al. Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial. Ann Surg 2009;249:1023-1031.   DOI   ScienceOn